The Role of Minocycline in the Treatment of Nosocomial Infections Caused by Multidrug, Extensively Drug and Pandrug Resistant Acinetobacter baumannii: A Systematic Review of Clinical Evidence

Microorganisms

Garyfallia Poulakou¹  Vasiliki Rapti¹  Despoina Koulenti¹  Dimitrios K. Matthaiou¹  Andromachi Blizou²  Sotirios Tsiodras³  Paraskevi C. Fragkou³  Myrto Blizou³  Drosos E. Karageorgopoulos³  Antonios Papadopoulos³ 

[1] 12462 Athens, Greece;3rd Department of Medicine, Sotiria General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece;4th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens;

关键词: minocycline;    nosocomial infections;    Acinetobacter baumannii;    antimicrobial drug resistance;    MDR;    XDR;    PDR;   

DOI  :  10.3390/microorganisms7060159

来源: DOAJ

【 摘 要 】

Treatment options for multidrug resistant Acinetobacter baumannii strains (MDR-AB) are limited. Minocycline has been used alone or in combination in the treatment of infections associated with AB. A systematic review of the clinical use of minocycline in nosocomial infections associated with MDR-AB was performed according to the PRISMA-P guidelines. PubMed-Medline, Scopus and Web of Science ^TM databases were searched from their inception until March 2019. Additional Google Scholar free searches were performed. Out of 2990 articles, 10 clinical studies (9 retrospective case series and 1 prospective single center trial) met the eligibility criteria. In total, 223 out of 268 (83.2%) evaluated patients received a minocycline-based regimen; and 200 out of 218 (91.7%) patients with available data received minocycline as part of a combination antimicrobial regimen (most frequently colistin or carbapenems). Pneumonia was the most common infection type in the 268 cases (80.6% with 50.4% ventilator-associated pneumonia). The clinical and microbiological success rates following minocycline treatment were 72.6% and 60.2%, respectively. Mortality was 20.9% among 167 patients with relevant data. In this systematic review, minocycline demonstrated promising activity against MDR-AB isolates. This review sets the ground for further studies exploring the role of minocycline in the treatment of MDR-AB associated infections.

【 授权许可】

Unknown